Welcome to our dedicated page for Axsome Therapeut news (Ticker: AXSM), a resource for investors and traders seeking the latest updates and insights on Axsome Therapeut stock.
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a biopharmaceutical company focused on central nervous system (CNS) conditions, and its news flow reflects both commercial performance and clinical development across this neuroscience portfolio. On this page, readers can follow AXSM news related to its FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as updates on its late-stage and other development programs.
Company announcements frequently cover net product revenue for AUVELITY, SUNOSI, and SYMBRAVO, as reported in quarterly financial results and preliminary revenue updates. These releases, often furnished to the SEC via Form 8-K, provide insight into prescription trends, payer coverage metrics, and the contribution of each product to Axsome’s overall revenue base.
Axsome’s news also highlights key clinical and regulatory milestones. Examples include initiation of the FORWARD Phase 3 trial of AXS-14 in fibromyalgia, FDA acceptance and Priority Review of a supplemental New Drug Application for AXS-05 in Alzheimer’s disease agitation, and pre-NDA meeting outcomes supporting an NDA submission for AXS-12 in narcolepsy. Additional items describe progress of solriamfetol in multiple Phase 3 programs and the acquisition of AZD7325 for potential use in epilepsy.
Investors and followers of AXSM stock can use this news feed to monitor earnings releases, pipeline data presentations at scientific meetings, regulatory designations, business development transactions, and Axsome’s participation in healthcare and biopharma investor conferences. Bookmarking this page allows for efficient tracking of how Axsome advances its CNS portfolio and communicates with the market over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Axsome Therapeutics (NASDAQ: AXSM) announced five abstracts to be presented at the 2023 American Academy of Neurology (AAN) Annual Meeting from April 22-27, showcasing new findings from the SHARP study. This study involved 59 patients suffering from excessive daytime sleepiness (EDS) related to obstructive sleep apnea (OSA) and cognitive impairment. Results indicated that solriamfetol, Axsome's treatment, demonstrated a potential clinical benefit, suggesting it as a viable option for EDS management in OSA patients. Presentations will also cover solriamfetol's pharmacological effects and ongoing real-world studies. Key presentations include results demonstrating solriamfetol's efficacy and ongoing clinical trials for migraine treatment with AXS-07.
Axsome Therapeutics (NASDAQ: AXSM) announced that CEO Herriot Tabuteau will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023, at 1:30 p.m. ET. This event will provide insights into the company's novel therapies for central nervous system disorders. Interested parties can access a live webcast and an archive of the discussion on the Investors section of Axsome's website. The company focuses on developing innovative treatments for CNS conditions, aiming to enhance patient care. Forward-looking statements in the release highlight potential future developments, including risks and uncertainties surrounding product success and regulatory approvals.
Axsome Therapeutics, Inc. (NASDAQ: AXSM) has announced a conference call scheduled for May 8, 2023, at 8:00 a.m. Eastern Time to discuss its financial results for the first quarter of 2023. This call will be held prior to the opening of U.S. financial markets and will also provide a business update. Interested participants can access the live conference call by dialing (877) 405-1239 or through a webcast on the company’s website. Axsome specializes in developing therapies for central nervous system (CNS) disorders and is focused on transforming treatment options with novel approaches. The company highlights its commitment to improve patients' lives by offering new therapeutic avenues for physicians.
Axsome Therapeutics (NASDAQ: AXSM) announced CEO Herriot Tabuteau will join a fireside chat at Cowen's 43rd Annual Health Care Conference on March 8, 2023, at 2:10 p.m. ET in Boston. The event aims to showcase Axsome's innovative therapies for CNS disorders. Interested parties can access a live webcast of the discussion through the company's website.
Axsome focuses on developing novel treatment options for CNS conditions with limited remedies available. The company emphasizes its commitment to improving patient care and advancing drug development.